SPY337.44+4.64 1.39%
DIA280.04+2.85 1.03%
IXIC11,012.24+229.42 2.13%

Eli Lilly, Boehringer Ingleheim Report FDA Endocrinologic and Metabolic Drugs Advisory Committee Vote 14-2 Benefits Of Empagliflozin 2.5mg Do Not Outweigh Risks

Benzinga · -